Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Intravenous InfusionsXGHA:IIL +8.86% Market Cap is GHS0.00 Mil as of Jul. 30, 2026. Among 1,024 Drug Manufacturers companies, Intravenous Infusions ranks worse than 97656.15% on this metric.
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Intravenous Infusions's Enterprise Value for Today is GHS0.00 Mil.
Intravenous Infusions (XGHA:IIL) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions Market Cap Chart
Intravenous Infusions Annual Data
Trend
Market Cap
Intravenous Infusions Semi-Annual Data
Market Cap
XGHA:IIL vs PTLF, PCYN, YBAO: Market Cap Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Intravenous Infusions's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Intravenous Infusions Market Cap vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Intravenous Infusions's Market Cap distribution charts can be found below:
* The bar in red indicates where Intravenous Infusions's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Intravenous Infusions's Market Cap for the fiscal year that ended in . 20 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Intravenous Infusions (XGHA:IIL) has a Market Cap of GHS0.00 Mil as of Jul. 30, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intravenous Infusions and its competitors. According to the industry distribution chart, Intravenous Infusions ranks #999999 out of 1024 companies in the Drug Manufacturers industry.
Is Intravenous Infusions' Market Cap too high?
Intravenous Infusions' current Market Cap is GHS0.00 Mil. Based on the distribution chart, Intravenous Infusions ranks #999999 out of 1024 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers.
How does Intravenous Infusions' Market Cap compare to PTLF and PCYN?
According to the Drug Manufacturers industry distribution chart, Intravenous Infusions ranks #999999 out of 1024 companies for Market Cap. This places Intravenous Infusions in the lower half of its industry. The industry median Market Cap is 212.26. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Drug Manufacturers company?
The median Market Cap among Drug Manufacturers companies is 212.26, based on 1,024 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Intravenous Infusions and its competitors. For the Drug Manufacturers industry, the median Market Cap is 212.26 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Intravenous Infusions's current Market Cap is GHS0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Intravenous Infusions stock overvalued right now?
Intravenous Infusions (XGHA:IIL) has a current Market Cap of GHS0.00 Mil. The current Market Cap is GHS0.00 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Intravenous Infusions (XGHA:IIL), the current Market Cap is GHS0.00 Mil as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Intravenous Infusions Ltd engages in the production of intravenous infusion and small-volume injectables for therapeutic purposes. The product categories are IV fluids, giving sets, and small-volume injectables. The company earns a majority of its revenue from IV fluids. Some of the IV fluids are sodium chloride solutions, dextrose solutions, dextrose saline solutions, and dextran solutions. Small-volume injectables include pethidine injection, magnesium sulphate injection, and quinine injection. Giving sets include plain giving sets, and blood giving sets.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XGHA:IIL has been successfully added to your 
